Psoriasis: rationale for targeting IL-17
British Journal of Dermatology, 06/21/2012
Girolomoni G et al. – Interleukin (IL)–17A is an attractive therapeutic target, which may allow selective intervention to address the dysregulated immune system in plaque psoriasis.



